Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response

Patients with heart failure and preserved ejection fraction (HFpEF) have a poor prognosis, and no therapies have been proven to improve outcomes. It has been proposed that heart failure, including HFpEF, represents overlapping syndromes that may have different prognoses. We present an exploratory study of patients enrolled in the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I‐PRESERVE) using latent class analysis (LCA) with validation using the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)‐Preserved study to identify HFpEF subgroups.

[1]  Michael A. Burke,et al.  Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[2]  Emily C. O'Brien,et al.  Clinical Implications of Chronic Heart Failure Phenotypes De fi ned by Cluster Analysis , 2015 .

[3]  L. de las Fuentes,et al.  Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. , 2014, Journal of the American College of Cardiology.

[4]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[5]  T. Sanai,et al.  Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy☆ , 2013, Current therapeutic research, clinical and experimental.

[6]  D. Levy,et al.  Predictors of New-Onset Heart Failure: Differences in Preserved Versus Reduced Ejection Fraction , 2013, Circulation. Heart failure.

[7]  J. McMurray,et al.  What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? , 2012, Journal of the American College of Cardiology.

[8]  M. Bristow,et al.  A Personalized BEST: Characterization of Latent Clinical Classes of Nonischemic Heart Failure That Predict Outcomes and Response to Bucindolol , 2012, PloS one.

[9]  D. Brutsaert,et al.  Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction. , 2012, Journal of the American College of Cardiology.

[10]  Sameer Ather,et al.  Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. , 2012, Journal of the American College of Cardiology.

[11]  Stephanie T. Lanza,et al.  Latent Class Analysis: An Alternative Perspective on Subgroup Analysis in Prevention and Treatment , 2013, Prevention Science.

[12]  R. McKelvie,et al.  Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial , 2011, Circulation. Heart failure.

[13]  B. Borlaug,et al.  Response to de Keulenaer and Brutsaert , 2011 .

[14]  G. D. De Keulenaer,et al.  Systolic and Diastolic Heart Failure Are Overlapping Phenotypes Within the Heart Failure Spectrum , 2011, Circulation.

[15]  B. Massie,et al.  Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection FractionClinical Perspective , 2011 .

[16]  B. Massie,et al.  Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial , 2011, Circulation. Heart failure.

[17]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[18]  R. Vasan,et al.  Epidemiology and clinical course of heart failure with preserved ejection fraction , 2011, European journal of heart failure.

[19]  D. DeMets,et al.  Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction: Findings From the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) , 2011, Circulation. Heart failure.

[20]  D. DeMets,et al.  Factors Associated With Outcome in Heart Failure With Preserved Ejection FractionClinical Perspective , 2011 .

[21]  H. Koide,et al.  Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy , 2010, Kidney and Blood Pressure Research.

[22]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[23]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[24]  Gissi-Hf Investigators.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[25]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[26]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[27]  D. Sane,et al.  Angiotensin II Type 1 Receptor Blockade Prevents Alcoholic Cardiomyopathy , 2006, Circulation.

[28]  D. Jacobs,et al.  Prognostic value of a novel classification scheme for heart failure: the Minnesota Heart Failure Criteria. , 2006, American journal of epidemiology.

[29]  John Chambers,et al.  The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors , 2005, Heart.

[30]  N. Freemantle,et al.  Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.

[31]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[32]  G. Wolf,et al.  Leptin and renal disease. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  David Rindskopf,et al.  THE USE OF LATENT CLASS ANALYSIS IN MEDICAL DIAGNOSIS , 2002 .

[34]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  S G Chrysant,et al.  Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension , 2001, Journal of clinical hypertension.